Results of Operations and Financial Condition. On August 17, 2026, DataMEDS AI, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026, and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act o…

Other Events. As previously announced by Data MEDS AI, Inc. (the “ Company ”) and Datavault AI Inc., a Delaware corporation (“ Datavault ”), Datavault will be making a voluntary one-time distribution (the “ Distribution ”) of Dream Bowl 2026 Meme Coin tokens (such tokens, the “ Meme Coins ”) to the record holders of DataMEDS common stock, par value $0.0001 per share (such stock, the “ DataMEDS Common Stock ” and such record holders, the “ Record Holders ”) as of the close of business on Augus…

Entry into a Material Definitive Agreement. As previously disclosed on May 20, 2026, DataMEDS AI, Inc. (formerly Wellgistics Health, Inc.) (the “Company”) entered into a Fully Binding Term Sheet, dated May 18, 2026, with EOS Technology Holdings, Inc. (“EOS”), Scilex Holding Company (“Scilex”), Datavault AI Inc. (“Datavault”), HealthBridge Advisors, LLC (“HBA”), and Fortitude Advisors, LLC (“Fortitude”). On July 29, 2026, the Company entered into an Amended and Restated Letter of Intent (the “…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing As previously disclosed, on April 13, 2026, the Wellgistics Health, Inc. (the “Company”) received a letter (“Letter”) from Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Form 10-K”), did not satisfy the continued listing require…

The Notes, the PIPE Warrants, the Placement Agent Warrants, the Series A Preferred Stock issuable upon conversion of the Notes, the shares of Common Stock issuable upon conversion of the Notes and the Series A Preferred Stock, and the shares of Common Stock issuable upon exercise of the Warrants were, or will be, offered and sold in transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on Section 4(a)(2) of the Securities Act an…

Regulation FD Disclosure. On May 27, 2026, the Company issued a press release announcing the financing and debt restructuring transaction described above under

Entry into a Material Definitive Agreement. Securities Purchase Agreement On May 27, 2026, Wellgistics Health, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers convertible promissory notes in the aggregate principal amount of $21,132,812.50 (the “Notes”) and warrants to purchase shares of the Company’s common s…

Entry into a Material Definitive Agreement. On May 20, 2026, Wellgistics Health, Inc. (the “Company”) entered into a Fully Binding Letter of Intent, dated May 20, 2026 (the “Term Sheet”), with EOS Technology Holdings, Inc. (“EOS”), Scilex Holding Company / Scilex Holdings, Inc. (“SCLX”), Datavault AI, Inc. (“Datavault”), HealthBridge Advisors, LLC (“HBA”), and Fortitude Advisors, LLC (“Fortitude”). The Term Sheet sets forth the parties’ current proposal with respect to a proposed transaction…

Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Unregistered Sales of Equity Securities. The information set forth in

Material Modification to Rights of Security Holders. To the extent required by

The excerpt does not provide specific details about any management change.

Regulation FD Disclosure. On May 19, 2026, the Company issued a press release, a copy of which is furnished as Exhibit 99.1 hereto. The information in this Item 7.01, including Exhibits 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, regardless of any gene…

The information furnished under this Item 2.02, including the referenced exhibit, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by reference to such filing.

Entry into a Material Definitive Agreement. On May 1, 2026, Wellgistics, LLC (“Wellgistics”), a wholly owned subsidiary of Wellgistics Health, Inc. (the “Company”), entered into an Acknowledgment of Indebtedness, Forbearance and Repayment Agreement (the “Forbearance Agreement”) with Marco Capital, Inc. (“MCI”). The Company, together with certain members of management, also entered into the Forbearance Agreement for purposes of reaffirming certain guaranty and related obligations. Under the Fo…

of the Original Report is hereby amended and restated in its entirety as follows: On February 9, 2026, Wellgistics Health, Inc. (the “Company”) entered into an Amended Settlement Agreement (the “Amended Settlement Agreement”) with Silverback Capital Corporation, which amended that certain Settlement Agreement previously referenced in the Original Report (the “Original Settlement Agreement”). The Company is filing this Amendment No. 1 to clarify that the entry into the Amended Settlement Agree…

Entry into a Material Definitive Agreement. On April 13, 2026, Wellgistics Health, Inc. (the “Company”) entered into a Collaboration Agreement (the “Collaboration Agreement”) with Kare Rx Hub, LLC (“Kare Hub”), Kare Pharmtech, LLC (“Kare Pharmtech”), and Healthstar Technologies, LLC (“Healthstar”), pursuant to which the parties agreed to collaborate through a newly formed limited liability company structure. The Collaboration Agreement provides for the creation of a separate limited liability…

Unregistered Sales of Equity Securities. As described under

Regulation FD Disclosure. On April 14, 2026, the Company issued a press release announcing the execution of a definitive joint venture agreement with Kare Pharmtech’s wholly owned subsidiary, Kare Rx Hub, LLC, and related matters. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 19…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 13, 2026, Wellgistics Health, Inc. (the “Company”) received a written notification (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2,500,000 in stock…

Unregistered Sales of Equity Securities. As described under

Entry into a Material Definitive Agreement. On April 13, 2026, Wellgistics Health, Inc. (the “Company”) entered into a Collaboration Agreement (the “Collaboration Agreement”) with Kare Rx Hub, LLC (“Kare Hub”), Kare Pharmtech, LLC (“Kare Pharmtech”), and Healthstar Technologies, LLC (“Healthstar”), pursuant to which the parties agreed to collaborate through a newly formed limited liability company structure. The Collaboration Agreement provides for the creation of a separate limited liability…

Regulation FD Disclosure. On April 14, 2026, the Company issued a press release announcing the execution of a definitive joint venture agreement with Kare Pharmtech’s wholly owned subsidiary, Kare Rx Hub, LLC, and related matters. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 19…

Entry into a Material Definitive Agreement Termination of Settlement Agreement On April 3, 2026, Wellgistics Health, Inc. (the “Company”) delivered written notice to Silverback Capital Inc. terminating that certain Settlement Agreement and Stipulation, dated January 28, 2026 (the “Settlement Agreement”), previously entered into between the Company and Silverback Capital Inc. The Settlement Agreement contemplated the issuance of shares of the Company’s common stock in reliance upon Section 3(a…

Creation of a Direct Financial Obligation or an Obligation Under an Off-balance Sheet Arrangement of a Registrant . The information set forth under